TRV GP IV, LLC
13F holdings for Q2 2026 · Boston, MA · filed August 10, 2026
TRV GP IV, LLC reported $254M in 13F securities across 2 holdings for Q2 2026, in a Form 13F filed August 10, 2026. The largest positions were MAZE (52.6%), TNGX (47.4%). Reported value fell 5.0% from the quarter before.
- 13F value Q2 2026
- $254M
- Holdings
- 2
- Change vs prior quarter
- -5.0%
- Rank by 13F value
- #5,759
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| MAZE Maze Therapeutics Inc. | $134M | 52.6% | 4,473,958 | 0% | Unchanged |
| TNGX Tango Therapeutics Inc. | $120M | 47.4% | 6,374,574 | 0% | Unchanged |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $254M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
None this quarter.
Biggest sells in Q2 2026
None this quarter.
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 0 new, 0 added, 0 trimmed, 0 sold out.
13F value by quarter
Questions about TRV GP IV, LLC
- What does TRV GP IV, LLC own?
- In its Form 13F for Q2 2026, TRV GP IV, LLC reported 2 holdings worth $254M. The five largest were MAZE, TNGX.
- What did TRV GP IV, LLC buy and sell in Q2 2026?
- TRV GP IV, LLC opened 0 new positions, added to 0, trimmed 0 and sold out of 0 compared with the quarter before.
- When did TRV GP IV, LLC file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 10, 2026.
From Form 13F filed by TRV GP IV, LLC (SEC CIK 0001688325) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds · Get this as JSON